Objective: We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes.
M ucinous ovarian adenocarcinomas are rare, comprising 2% to 3% of primary epithelial ovarian malignancies. 1, 2 These tumors are often misdiagnosed as primary ovarian tumors rather than nonovarian metastases. Other sites of origin to consider in the differential diagnosis of these tumors include the upper and lower gastrointestinal (GI) tracts, the pancreaticobiliary tract, and the lung. In 2011, Zaino et al 3 published sentinel findings that highlighted the true rarity of primary mucinous ovarian cancers (PMOCs). The authors comprehensively reviewed a primary mucinous adenocarcinoma subset of 3400 epithelial ovarian malignancies and reclassified 29 (71%) of 41 cases as metastatic, rather than primary, to ovary. 3 Although most patients present with a dominant mass and stage I disease, 2 some will present with bilateral, smaller sized ovarian tumors or advanced-stage disease. In these settings, clinical correlation and review of imaging, with expert gynecologic pathology assessment, are essential to discern a primary from metastatic carcinoma. Upper and lower endoscopy, and focused imaging, may help preclude a diagnosis of a GI, pancreatic, biliary, or appendiceal malignancy. Immunohistochemistry may aid in the diagnosis, and many of the markers used to discern mucin-producing carcinomas, such as diffuse cytokeratin-7 staining and absent cytokeratin-20 staining, have been incorporated in the diagnosis of these tumors. 1, 4 The primary strategy for treating mucinous carcinomas of the ovary is surgical resection with staging. Unless fertility preservation is considered, surgery typically entails hysterectomy, bilateral salpingo-oophorectomy, and omentectomy; regional lymph node dissection can be included. 5 Many gynecologic oncologists advocate an appendectomy only with obvious tumor involvement or if the appendix appears abnormal at the time of staging. 6Y8 Adjuvant treatment ranges from observation in early-stage disease to systemic chemotherapy using both GI and epithelial ovarian treatment regimens. 9 The PMOC is considered a relatively chemoresistant disease, with poor outcomes, compared stage for stage with the more common high-grade serous epithelial ovarian cancer. 10 As with epithelial ovarian malignancies, surgical cytoreduction is recommended for advanced-stage PMOC because this has been shown to improve outcomes. 5, 6 Considering the rarity, diagnostic challenges, and wide variability of surgical and adjuvant treatment approaches in PMOC, we sought to review an international experience of PMOCs across 3 tertiary medical centers with expert pathology assessment to confirm diagnoses. We hypothesized that there could be significant heterogeneity in patient characteristics and surgical treatment across the institutions. Here, we describe a large cohort of patients with PMOC to evaluate differences in patient characteristics, surgical and adjuvant treatment strategies, and outcomes.
METHODS
This was an institutional review boardYapproved retrospective review. We identified all cases of PMOC using institutional datasets of patients treated at Memorial Sloan Kettering Cancer Center (MSK) in the United States from 1998 to 2013, Rigshospitalet (DEN) in Denmark from 2005 to 2013, and Gustave Roussy Cancer Campus (GRCC) in France from 1976 to 2014. Cases of pure borderline pathology, intraepithelial carcinoma, or metastatic mucinous carcinoma from another site were excluded. All tumors were reviewed by an expert gynecologic pathologist within each respective center. Each center used identical, mutually-agreed-on clinical and histologic criteria to confirm a PMOC diagnosis; patients who presented with a unilateral ovarian tumor greater than 10 cm in size were included, and in patients with bilateral tumors or a tumor less than 10 cm in size, a GI workup often was performed to rule out a GI primary. Cytokeratin-7, cytokeratin-20, and caudal-type homeobox 2 staining, if available, were used to support the diagnosis. Clinical and pathologic data were abstracted from medical records, and a deidentified dataset was compiled and processed at a single institution. The MSK and GRCC data were retrospectively collected from patients' electronic medical records. The DEN data were retrieved from a national clinical quality data registry that includes many clinical variables but have incomplete treatment data. 11 Patients were staged according to the 2014 International Federation of Gynecology and Obstetrics classification system. Histologic grading was performed according to the Prat grading system for GRCC and DEN cases, and the Shimizu and Silverberg system 12 for MSK cases.
Statistical Analysis
Variable differences among the 3 centers or between defined cohorts were tested using the Fisher exact test for categorical variables and Kruskal-Wallis test/Wilcoxon rank sum test for continuous variables. A P value less than 0.05 was considered statistically significant. Progression-free survival (PFS) was defined as the time between the date of first surgery to the date of progression, death, or last follow-up. Both progression and death were considered as events in our survival analysis. Median PFS and PFS rate were estimated using the Kaplan-Meier method. P values were obtained through a fitting marginal Cox proportional hazards model by incorporating centers as clusters. 13 A log-rank P value was used to examine the PFS differences among centers. All analyses were performed by MSK's Biostatistics Department using SAS9.4 (Cary, NC) and R3.2. software (R Project for Statistical Computing)
RESULTS
Of 537 patients initially evaluated for inclusion across the three institutions, 222 (41%) met the inclusion criteria. At MSK, 175 patients were initially evaluated for inclusion, of whom 34 met the inclusion criteria. Of the 141 remaining patients who were excluded, 62 had borderline tumors, 24 had microinvasive tumors, 12 had metastasis to ovary, 4 had tumor of mixed histology, 38 had advanced-stage disease at presentation, and 1 had a dual malignancy. At GRCC, 350 patients were initially evaluated for inclusion, of whom 111 met the inclusion criteria. The remaining 239 patients were excluded for the following reason(s): they had metastatic disease from another primary; they were seen at the institution as a second opinion, with no clinical follow-up; or they had tumor of mixed histology or a borderline mucinous tumor. At DEN, 95 patients were initially evaluated for inclusion, of whom 77 met the inclusion criteria. Of the remaining 18 patients who were excluded, 14 had borderline tumors and 4 had metastasis to ovary.
Overall Cohort
The median age of the overall cohort was 49 years (range, 15Y89 years). Fifty-one (49%) of 104 patients had an elevated CA-125 level (935 U/mL) at diagnosis. The median tumor size was 15 cm (range, 5Y36 cm). In the 141 patient records with laterality data available, 134 (95%) unilateral tumors were documented. Among unilateral tumors with tumor size data available, 107 (88%) of 122 were 10 cm or greater. Of the 177 tumors that were histologically graded, 109 (62%) were grade 1 and 68 (38%) were grade 2 or 3. Thirty-seven (26%) and 41 (28%) of 145 patients underwent upper or lower endoscopy, respectively. Any endoscopic evaluation was performed in 48 (33%) of 145 patients.
Of the 221 patients with documented staging details, 163 had stage I (74%), 8 had stage II (4%), 40 had stage III (18%), and 10 had stage IV (5%) disease. Hysterectomy was performed in 164 (75%) of 220 patients, peritoneal cytology in 206 (93%) of 222, bilateral salpingo-oophorectomy in 173 (81%) of 214, appendectomy in 168 (80%) of 210, omentectomy in 196 (90%) of 217, pelvic lymphadenectomy in 92 (42%) of 219, and paraaortic lymphadenectomy in 83 (38%) of 219 patients. The median number of pelvic lymph nodes resected was 14 (range, 1Y34), and the median number of paraaortic lymph nodes resected was 11 (range, 1Y46) ( Table 1) . Table 1 details demographic characteristics, staging procedures, and treatment strategies across the 3 centers. The median age was 39 years (range, 15Y83) in the GRCC cohort, 60 years (range, 21Y89 years) in the DEN cohort, and 54 years (range, 20Y86 years) in the MSK cohort (P G 0.001). In the overall cohort, 78 (37%) of 213 patients were smokers V 20 (19%) of 105 in the GRCC group, 44 (59%) of 75 in the DEN group, and 14 (42%) of 33 in the MSK group (P G 0.001). In the overall cohort, 41 (19%) of 215 patients were managed using a fertility-preservation approach V 32 (29%) of 111 in the GRCC group, 1 (1%) of 70 in the DEN group, and 8 (24%) of 34 in the MSK group (P G 0.001). Of the 220 patients with reported hysterectomy status, 70 (63%) of 111 in the GRCC group, 68 of (91%) 75 in the DEN group, and 26 (77%) of 34 in the MSK group underwent hysterectomy before or during the index surgery (P G 0.001). Of the 214 patients with reported oophorectomy status, 79 (71%) of 111 in the GRCC group, 68 (99%) of 69 in the DEN group, and 26 (77%) of 34 in the MSK group underwent bilateral oophorectomy before or during the index surgery (P G 0.001). We evaluated staging procedures while controlling for age that were statistically significant on univariate analysis across centers. Patients were grouped according to age younger than 45 years or 45 years and older because this is the upper age limit for consideration of fertility-preservation procedures. In patients who underwent a hysterectomy, there was no association with either age group across each center. There was a difference across centers regarding the performance of pelvic and paraaortic lymph node dissection, with MSK performing more nodal dissections in both age groups compared with the other centers in this series (Table 2 ).
Comparisons Across Centers
In the overall cohort, 99 (45%) of 219 patients underwent a pelvic and/or paraaortic lymphadenectomy. A pelvic lymphadenectomy was performed in 37 (35%) of 107 patients in the GRCC group, 26 (35%) of 74 in the DEN group, and 29 (85%) of 34 in the MSK group (P G 0.001). A paraaortic lymphadenectomy was performed in 42 (38%) of 111, 14 (19%) of 74, and 27 (79%) of 34, respectively (P G 0.001). In the overall cohort, 76 (47%) of 163 patients with stage I disease underwent lymphadenectomy. Twenty-three (42%) of 55 patients with stage II or higher disease underwent lymphadenectomy (Table 1) .
Of the 221 patients in the overall cohort with reported International Federation of Gynecology and Obstetrics stage status, 85 (77%) of 111 in the GRCC group, 52 (68%) of 76 in the DEN group, and 26 (81%) of 32 in the MSK group presented with stage I disease (P = 0.454). Of the 177 tumors in the overall cohort that were histologically graded, 43 (59%) of 73, 46 (64%) of 72, and 20 (63%) of 32, respectively, were grade 1. There were no statistically significant differences in median tumor size, stage or grade distribution, rates of appendectomy or omentectomy, or use of adjuvant chemotherapy.
Fertility Preservation
Patients undergoing surgery for stage I PMOC who were aged younger than 45 years were identified and analyzed separately. Fertility preservation in this group of patients was defined as the retention of 1 ovary and uterus at the time of primary surgery. Of the 76 patients aged younger than 45 years, 32 (42%) underwent initial fertility-preserving surgery (Table 3) . Of these 32 patients, 26 (81%) were from GRCC, 0 (0%) were from DEN, and 6 (19%) were from MSK. The median age at diagnosis of the fertility-preserved group was 26 years (range, 15Y40 years); it was 38 years (range, 17Y45 years) for the remaining 44 patients who did not undergo fertilitypreserving surgery (P G 0.001). Six (19%) of the 32 patients who underwent fertility preservation underwent a combined upper and lower GI endoscopic evaluation compared with 12 (33%) of the 36 remaining patients (P = 0.271). Median CA-125 was elevated in 5 (24%) of 21 and 8 (35%) of 23 patients, respectively (P = 0.518). Median tumor size was 15 cm (range, 5Y36 cm) and 13 cm (range, 8Y30 cm), respectively (P = 0.533).
None of the patients in the fertility-preservation group had positive cytology compared with 4 (10%) of 41 in the remaining patients. An appendectomy was performed in 27 (84%) of 32 and 35 (85%) of 41 patients, respectively (P = 1). A pelvic lymphadenectomy was performed in 13 (41%) of 32 and 17 (44%) of 44 patients, respectively (P = 1). The median number of pelvic lymph nodes removed was 14 (range, 1Y34 nodes) and 13 (range, 5Y33 nodes), respectively. A paraaortic lymphadenectomy was performed in 16 (50%) of 32 and 15 (34%) of 44 patients, respectively (P = 0. 237). The median number of paraaortic lymph nodes removed was 9 (range, 2Y29 nodes) and 13 (range, 2Y42 nodes), respectively (P = 0.1). Six (25%) of 24 tumors in the fertility-preservation group were grade 2 or higher compared with 10 (31%) of 32 tumors in the remaining group (P = 0.767). Pregnancy data were not collected. 
Adjuvant Treatment
The GRCC and MSK had data regarding adjuvant treatment. Of the 145 patients (65%) who had treatment data available, 68 (47%) received systemic cytotoxic treatment, with a median of 6 cycles (range, 1Y12). Chemotherapy treatments were categorized as gynecologic (GYN) or GI regimens. A GYN regimen entailed platinum plus taxane chemotherapy. Gastrointestinal treatment regimens contained combinations of cisplatin, 5-fluorouracil, capecitabine, gemcitabine, or oxaliplatin. Fifty-five (81%) of 68 patients were treated with a GYN regimen, 13 (19%) with a GI regimen ( Table 1) . Thirty (79%) of 38 patients with stage I/II disease were treated with a GYN regimen and 8 (21%) were treated with a GI regimen. Twenty-five (83%) of 30 patients with stage III/IV disease were treated with a GYN regimen and 5 (17%) were treated with a GI regimen. No association was noted between type of chemotherapy regimen and stage of disease (P = 0.76).
Six (19%) of 32 patients who underwent fertilitypreservation surgery received chemotherapy compared with 14 (39%) of the remaining 36 patients in the cohort (P = 0.109). The median number of chemotherapy cycles was 5 (range, 3Y9 cycles) and 6 (range, 4Y8 cycles), respectively. A GYN chemotherapy regimen was used in 4 (67%) of 6 and 11 (79%) of 14 patients, respectively. A GI chemotherapy regimen was used in 2 (33%) of 6 and 3 (21%) of 14 patients, respectively (Table 3) .
Survival
Univariate PFS analysis was performed for the total cohort. Within a median follow-up of 72.2 months (range, 6Y365 months), there were 44 recurrences. The median PFS for the total cohort was 255 months (95% confidence interval
[CI], 103Y382), with a 5-year PFS rate of 65% (95% CI, 58%Y71%) (Fig. 1) .
Univariate PFS analysis was performed separately for the younger-than-45 cohort. There were 8 recurrences (25%) among the 32 patients who underwent fertility-preserving surgery compared with 9 recurrences (20%) among the 44 patients who did not undergo fertility-preserving surgery. The median PFS was not reached in the former group and was 382 months (95% CI, not estimable) in the latter group. The 5-year PFS rates were 73% (95% CI, 50%Y86%) and 84% (95% CI, 70%Y92%), respectively (P = 0.043).
Univariate PFS analysis was performed for each center. The median follow-up was 82.4 months (range, 6Y365 months) in the GRCC cohort, 70.3 months (range, 6Y127 months) in the DEN cohort, and 70.4 months (range, 8Y200 months) in the MSK cohort (Fig. 1) . The median PFS in the GRCC cohort was 255 months (95% CI, 162Y382), with a 68% (95% CI, 58%Y76%) 5-year PFS rate. The median PFS in the DEN cohort was 88 months (95% CI, 36Ynot estimable), with a 60% (95% CI, 48%Y71%) 5-year PFS rate. The median PFS in the MSK cohort was not reached, with a 67% (95% CI, 46%Y81%) 5-year PFS rate (P = 0.275).
Univariate PFS analysis was performed by stage. The median PFS for patients with stage I to II disease was 382 months (95% CI, not estimable), with an 80% (95% CI, 73%Y85%) 5-year PFS rate. The median PFS for patients with stage III to IV disease was 11 months (95% CI, 8%Y14%), with a 17% (95% CI, 8%Y29%) 5-year PFS rate.
DISCUSSION
Our series represents a substantial cohort of patients with PMOC across 3 international centers, each of which is a In a highly cited publication, Seidman et al 2 reviewed a consecutive series of 52 mucinous ovarian carcinomas and sought to develop an algorithm to distinguish primary from metastatic mucinous carcinomas of the ovary. By applying size and laterality criteria, they correctly distinguished 90% of these tumors. Metastatic tumors were defined as bilateral or less than 10 cm in size; primary tumors were defined as unilateral and greater than 10 cm in size. 2 Further investigation is needed to reliably distinguish PMOC in advanced-stage cases from an extraovarian primary malignancy. In patients who do not conform to the classic presentation of this disease, additional efforts to rule out a metastatic mucinous tumor, including a GI endoscopic evaluation, are warranted.
Our cooperative effort highlights the challenges associated with multiinstitutional collaborations and affirms our initial hypothesis that there could be differences across institutions regarding patient characteristics and surgical staging strategy. We encountered specific population differences, which introduced heterogeneity to our data. For example, GRCC is a known referral site for fertility-preservation efforts in ovarian cancer, which is reflected in age at diagnosis and surgical procedures performed. At MSK, more lymph node dissections were performed. This heterogeneity also introduces referral bias, which can limit comparisons across centers. 
